Recent quarterly earnings reports and calls indicate ICU Medical achieved profitability in Q3 2026 with revenue of $560.4 million and net income of $26.8 million. The company highlighted product innovation, FDA clearances, and ongoing capital investments. The joint venture with Otsuka for IV Solutions continues to operate with ICU Medical retaining a 40% stake and commercial agreements for sales and distribution.

• ICU Medical reported Q3 2026 revenue of $560.4 million and net income of $26.8 million, with basic and diluted EPS of $1.07 per share [N1][N3].
• The company swung to a Q3 profit, reflecting operational improvements and product demand [N5].
• FDA 510(k) clearance was received in April 2025 for Plum Duo and Plum Solo precision infusion pumps, designed for accurate intravenous medication delivery and clinical workflow support [S1].
• ICU Medical continues to invest in manufacturing capacity and infusion pump placements, with capital expenditures estimated between $85 million and $100 million for 2026 [S1].
• The joint venture formed with Otsuka Pharmaceutical Factory America for IV Solutions remains operational, with ICU Medical holding a 40% ownership and selling products on behalf of the joint venture [S1].
• The company refinanced its credit facilities in October 2025, including a $750 million senior secured Term Loan A and a $500 million revolving credit facility, with $290 million in principal prepayments made in 2025 [S1].
• Manufacturing facilities are located in the U.S., Costa Rica, Mexico, and the Czech Republic, supporting global supply chain and production [S1].
• Risk factors disclosed in the 2025 Annual Report remain applicable with no material changes reported in the latest quarterly filing [S2].

ICU Medical’s broad and innovative product portfolio addresses critical needs in infusion therapy, oncology drug safety, and vital care, supported by recent FDA clearances and industry awards. The company’s strategic acquisitions and joint venture structure enable expanded market reach and operational efficiencies. Strong liquidity and capital investment plans support ongoing product development and manufacturing capacity. Integration of infusion pumps with safety software and electronic health records enhances clinical workflow and medication safety, potentially increasing customer adoption. Continued focus on innovation and clinical support services may strengthen ICU Medical’s position in hospital and outpatient care settings.

ICU Medical faces risks related to integration of acquired businesses and joint venture operations, which may affect operational efficiency. The medical device industry is subject to regulatory scrutiny, reimbursement pressures, and competitive dynamics that could impact product adoption and pricing. Capital expenditures and refinancing obligations require effective liquidity management. Potential supply chain disruptions or manufacturing challenges across multiple geographies could affect product availability. Changes in healthcare provider purchasing behavior or shifts in clinical practice could influence demand for ICU Medical’s products. The company’s reliance on key product lines and customers may expose it to concentration risks.

ICU Medical’s competitive advantages stem from its comprehensive and integrated product portfolio spanning infusion therapy, vascular access, oncology drug safety, and vital care, supported by proprietary technologies such as needlefree connectors and closed system transfer devices. The company’s Plum infusion pumps have received FDA clearance and industry recognition for safety and interoperability, including Best in KLAS awards and cybersecurity certification. Strategic acquisitions have expanded ICU Medical’s product breadth and global market presence, while the joint venture with Otsuka for IV Solutions leverages manufacturing scale and distribution. The company’s focus on clinical workflow integration, medication safety software, and professional services enhances customer retention and creates switching costs. Manufacturing footprint across multiple countries supports supply chain resilience. These factors collectively contribute to a differentiated position in the medical device infusion and vital care markets.

• Integration and Operational Risks: Challenges in integrating acquisitions and managing joint venture operations may impact efficiency and financial performance.
• Regulatory and Reimbursement Risks: Medical device products are subject to regulatory approvals and reimbursement policies that can affect market access and pricing.
• Liquidity and Capital Expenditure Risks: Significant capital investments and debt refinancing obligations require prudent liquidity management to support operations.
• Supply Chain and Manufacturing Risks: Disruptions in manufacturing facilities across multiple countries could affect product supply and delivery timelines.
• Market and Customer Concentration Risks: Dependence on key customers and product lines may expose the company to demand fluctuations and competitive pressures.

• ICU Medical, Inc. develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications globally.
• The company’s product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets; needlefree IV connectors; peripheral IV catheters; sharps safety products; sterile IV solutions via a joint venture; closed system transfer devices and pharmacy compounding systems; respiratory, anesthesia, patient monitoring, and temperature management products.
• Primary customers include acute care hospitals, wholesalers, ambulatory clinics, outpatient clinics, home health care providers, and long-term care facilities.
• ICU Medical has grown organically and through acquisitions, including Pfizer’s Hospira Infusion Systems in 2017, Pursuit Vascular in 2019, and Smiths Medical in 2022, broadening its product portfolio and global reach.
• In 2024-2025, ICU Medical divested a controlling interest (60%) in its IV Solutions business to Otsuka Pharmaceutical Factory America, forming a joint venture (Otsuka ICU Medical LLC) where ICU Medical retains 40% ownership and sells and distributes products on behalf of the joint venture.
• The Consumables business unit includes Infusion Therapy, Oncology, Vascular Access, and Tracheostomy products with key brands such as Clave™ needlefree connectors, Neutron™ catheter patency devices, Tego™ connectors, ClearGuard™ disinfection caps, ChemoLock™ and ChemoClave™ closed system transfer devices, Jelco® peripheral IV catheters, and Portex® tracheostomy tubes.
• The Infusion Systems business unit offers large volume pumps (Plum Duo™, Plum Solo™), ambulatory infusion pumps (CADD™), syringe infusion pumps (Medfusion™), and associated safety software platforms (LifeShield™, MedNet™, PharmGuard™).
• Plum precision pumps received FDA 510(k) clearance in April 2025 and are designed for accurate delivery of intravenous medications with features supporting clinical workflows and IV-EHR interoperability.
• The Vital Care business unit includes IV Solutions (now part of the joint venture), Hemodynamic Monitoring systems (Cogent™ 2-in-1, CardioFlo™), General Anesthesia & Respiratory products (Portex® bronchial hygiene), Temperature Management solutions (Level 1® warming systems), and Regional Anesthesia/Pain Management trays.
• Manufacturing facilities are located in the United States, Costa Rica, Mexico, and the Czech Republic.
• As of September 30, 2026, ICU Medical reported quarterly revenue of $560.4 million and net income of $26.8 million, with basic and diluted EPS of $1.07 per share.
• Liquidity metrics as of September 30, 2026, include cash and equivalents of $208.8 million, current assets of $1.22 billion, current liabilities of $514.6 million, a current ratio of 2.37, and a cash ratio of 0.43.
• Capital expenditures for 2026 are estimated in the range of $85 million to $100 million, focused on manufacturing expansion and infusion pump placements.
• The company refinanced its credit facilities in October 2025, including a $750 million senior secured Term Loan A and a $500 million revolving credit facility, with principal prepayments totaling $290 million in 2025.
• Recent quarterly earnings calls and reports indicate ICU Medical swung to a Q3 profit with positive revenue and earnings performance.
• The company continues to emphasize innovation, safety, and workflow efficiency in its product development and clinical support services.
• Risk factors disclosed in the 2025 Annual Report remain applicable with no material changes reported in the latest quarterly filing.